278 related articles for article (PubMed ID: 21272926)
1. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
[TBL] [Abstract][Full Text] [Related]
2. FaDu cell characteristics induced by multidrug resistance.
Ma J; Lu S; Yu L; Tian J; Li J; Wang H; Xu W
Oncol Rep; 2011 Nov; 26(5):1189-95. PubMed ID: 21833476
[TBL] [Abstract][Full Text] [Related]
3. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer.
Xie ZY; Lv K; Xiong Y; Guo WH
Oncol Res Treat; 2014; 37(11):666-8, 670-2. PubMed ID: 25427584
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of patupilone resistance.
Mozzetti S; Iantomasi R; De Maria I; Prislei S; Mariani M; Camperchioli A; Bartollino S; Gallo D; Scambia G; Ferlini C
Cancer Res; 2008 Dec; 68(24):10197-204. PubMed ID: 19074887
[TBL] [Abstract][Full Text] [Related]
6. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel.
Takara K; Obata Y; Yoshikawa E; Kitada N; Sakaeda T; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 2006 Dec; 58(6):785-93. PubMed ID: 16534613
[TBL] [Abstract][Full Text] [Related]
7. Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Yamaguchi T; Kurita T; Nishio K; Tsukada J; Hachisuga T; Morimoto Y; Iwai Y; Izumi H
Cancer Sci; 2015 Apr; 106(4):359-66. PubMed ID: 25611552
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
9. Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1.
Wang TH; Wan JY; Gong X; Li HZ; Cheng Y
Oncol Rep; 2012 Nov; 28(5):1681-6. PubMed ID: 22941407
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
11. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
14. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
15. Detection and characterization of side population in Ewing's sarcoma SK-ES-1 cells in vitro.
Yang M; Zhang R; Yan M; Ye Z; Liang W; Luo Z
Biochem Biophys Res Commun; 2010 Jan; 391(1):1062-6. PubMed ID: 20004177
[TBL] [Abstract][Full Text] [Related]
16. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
17. S100B promotes chemoresistance in ovarian cancer stem cells by regulating p53.
Yang T; Cheng J; You J; Yan B; Liu H; Li F
Oncol Rep; 2018 Sep; 40(3):1574-1582. PubMed ID: 29956807
[TBL] [Abstract][Full Text] [Related]
18. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the characteristics of side population cells in the human ovarian cancer cell line OVCAR-3].
Luo LJ; Zhao Z; Zeng JF; Liang B; Yang JX; Cao DY; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):281-5. PubMed ID: 22781115
[TBL] [Abstract][Full Text] [Related]
20. Pien Tze Huang suppresses the stem-like side population in colorectal cancer cells.
Wei L; Chen P; Chen Y; Shen A; Chen H; Lin W; Hong Z; Sferra TJ; Peng J
Mol Med Rep; 2014 Jan; 9(1):261-6. PubMed ID: 24173665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
